搜尋結果
Sarepta's Stock Soars on Best-Case FDA Decision for its Muscular Dystrophy Treatment ...
The Wall Street Journal· 14 小時前For biotech companies, regulatory approval is usually one of many steps needed to convince Wall ...
Stocks making the biggest moves midday: Sarepta Therapeutics, Hertz Global, Asana and more
CNBC· 12 小時前Shares of the biopharma company surged 33% after the U.S. Food and Drug Administration approved ...
Stocks making the biggest moves premarket: Gilead Sciences, Sarepta Therapeutics, Nike and more
CNBC· 17 小時前The decline comes after the AI chipmaker on Tuesday briefly topped Microsoft as the most ...
US FDA approves expanded use of Sarepta's Duchenne gene therapy
Reuters· 1 日前, opens new tab gene therapy for all patients with Duchenne muscular dystrophy aged ... ...
Gene Therapy for Kids’ Deadly Disease Wins Broader FDA Approval
Bloomberg· 1 日前Sarepta Therapeutics Inc.’s gene therapy received expanded US approval to include more children ...
Wall Street futures edge lower ahead of business survey data
Reuters· 18 小時前U.S. stock index futures edged lower on Friday as megacap tech and chip stocks lost ground, ...
Will Pfizer Stock Rebound To Its 2021 Highs Of $60?
Forbes· 5 日前Pfizer stock (NYSE: PFE) currently trades at $28 per share, 55% below its peak level of $61 seen in December 2021. PFE stock ...